Omeros Corporation OMER R2K
Healthcare · Biotechnology · United States
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
READ MORE ›$11.04
+257.28% 1Y
Market & Price
Market Cap
$799.02M
Current Price
$11.04
High / Low (52W)
$17.18 / $2.97
Beta
2.66
Valuation
Stock P/E
9.68
Industry PE
23.65
Forward P/E
-
PEG Ratio
0.81
Book Value
$-1.69
Price to Book
-6.53
P/S
80.77
EV/EBITDA
-8.53
Dividend Yield
-
Profitability & Returns
ROCE
-49.60%
ROE
-
ROA
-25.24%
Profit Margin
-
Op Margin
-
EPS (Latest Qtr)
$0.62
EPS (TTM)
$1.14
Balance Sheet & Liquidity
Debt/Equity
-
Quick Ratio
2.48
Current Ratio
3.03
Debt
$226.61M
Total Assets
$325.63M
Current Assets
$215.67M
Working Capital
$137.60M
Ownership
Promoter Holding
3.56%
Chg in Prom Hold
-
FII / Inst Holding
44.41%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$890.31M
Total Revenue (TTM)
$9.89M
EBITDA
$-104.33M
Free Cash Flow
$181.02M
Operating Cash Flow
$-94.76M
Shares Outstanding
72.38M
Gross Margin
-
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-
Profit 5Y
-35.69%
Revenue (YoY)
-
Earnings (YoY)
-
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -35.7% CAGR over 5 years.
- Trading 35.7% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OMER Omeros Corporation R2K | 11.04 | 9.68 | $799.02M | - | -49.60% | - | - | -35.69% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 1.59M | 1.66M | 4.61M | 22.02M | 21.78M | 26.75M | 29.86M | 33.42M | 23.54M | 13.53M | 26.11M | 10.63M | 21.06M | 28.82M | 30.00M | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 9.89M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | 587.00K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | 9.31M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.97M | 32.35M | 26.39M | 29.08M | 26.73M |
| Operating Income | -19.30M | -18.04M | -19.45M | -10.93M | -12.04M | -11.86M | -12.72M | -11.94M | -5.11M | -14.12M | -27.69M | -30.62M | -35.44M | -18.47M | -19.24M | -9.34M | -11.10M | -23.70M | -23.68M | -27.68M | -25.43M | -33.82M | -45.29M | -45.61M | -39.83M | -35.05M | -37.44M | -50.77M | -35.71M | -40.90M | -48.15M | -39.03M | -59.16M | - | - | -34.97M | -32.35M | -26.39M | -29.08M | -17.42M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -33.62M | -25.67M | -26.15M | -28.85M | 57.44M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.05M | 3.18M | 3.65M | 15.00K | - | - | 5.89M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -37.56M | -25.89M | -21.24M | 81.90M | 51.31M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | 57.00K |
| Net Income | -19.92M | -19.83M | -20.54M | -12.61M | -13.96M | -19.63M | -15.09M | -14.36M | -7.48M | -16.55M | -30.05M | -33.70M | -39.47M | -23.53M | -24.34M | -14.45M | -16.46M | -29.23M | -29.03M | -33.29M | -38.46M | -37.27M | -35.09M | -28.59M | -22.70M | -33.01M | -30.85M | -17.46M | -33.70M | -37.29M | -37.75M | -37.18M | -56.04M | - | - | -33.46M | -25.42M | -30.92M | 86.45M | 56.06M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.61 | -0.66 | - | -0.57 | -0.46 | -0.36 | -0.53 | -0.49 | -0.28 | -0.54 | -0.59 | - | -0.63 | -0.97 | - | - | -0.58 | -0.43 | -0.47 | 0.98 | 0.62 |
| R&D Expense | 13.26M | - | 15.43M | 10.23M | 12.49M | - | 12.24M | 13.14M | 14.84M | - | 18.14M | 19.41M | 26.86M | - | 26.25M | 19.11M | 23.75M | - | 28.91M | 24.13M | 31.32M | - | 32.50M | 30.13M | 25.82M | 24.09M | 23.52M | 38.57M | 24.61M | 29.64M | 31.73M | 26.77M | 45.35M | 24.08M | - | 23.85M | 22.01M | 15.99M | - | 13.36M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 64.83M | 29.87M | 111.81M | 73.81M | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 163.39M | 164.53M | 166.95M | 122.80M |
| Operating Income | -20.76M | -30.11M | -27.41M | -36.88M | -50.52M | -70.01M | -71.24M | -54.28M | -43.90M | -112.22M | -146.04M | -156.92M | - | -163.39M | -164.53M | -166.95M | -122.80M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -158.38M | -143.16M | -154.70M | -121.83M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | 19.67M | 22.70M | 30.84M | 24.68M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -182.03M | -174.92M | -180.32M | -2.80M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 2.31M | 2.01M |
| Net Income | -21.09M | -29.25M | -28.55M | -38.44M | -39.80M | -73.67M | -75.10M | -66.75M | -53.48M | -126.76M | -84.49M | -138.06M | - | 47.42M | -117.81M | -156.81M | -3.35M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -1.71 | -2.41 | - | 0.76 | -1.88 | -2.70 | -0.05 |
| R&D Expense | 16.93M | 23.46M | 23.72M | 31.92M | 36.30M | 47.95M | 48.38M | 50.70M | 55.60M | 89.86M | 106.32M | 107.61M | 118.78M | 112.72M | 114.87M | 119.52M | 81.30M |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -35.69% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +257.28% |
| 6 Months: | +16.83% |
| 3 Months: | -8.38% |
| 1 Month: | -24.18% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Oct 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 45.70M | 26.98M | 26.57M | 16.54M | 10.83M | 48.99M | - | 67.28M | 116.33M | 95.94M | 136.97M | 181.04M | - | 590.97M | 378.27M | 277.08M | 325.63M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 443.24M | 217.90M | 134.12M | 215.67M |
| Cash & Equivalents | 12.73M | 820.00K | 3.28M | 4.00M | 1.52M | 1.38M | 354.00K | 1.36M | - | 2.22M | 3.39M | 5.86M | 3.08M | 10.50M | - | 11.01M | 7.11M | 3.40M | 9.66M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 212.97M | 6.72M | 6.94M | 6.44M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 505.29M | 403.25M | 459.69M | 446.86M |
| Current Liabilities | - | - | 15.37M | 18.98M | 8.36M | 11.87M | 18.32M | 16.25M | - | 16.07M | 26.31M | 37.36M | 55.46M | 36.74M | - | 136.38M | 53.32M | 79.53M | 78.06M |
| Long Term Debt | - | - | - | 13.55M | 20.10M | 14.90M | 26.12M | 49.77M | 70.00M | 79.51M | 84.12M | - | - | - | - | 220.91M | 213.16M | 166.58M | 208.53M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 342.02M | 236.46M | 207.02M | 239.14M |
| Total Equity | -91.17M | 43.15M | 20.47M | -5.55M | -6.53M | -18.38M | -42.65M | -26.23M | - | -37.45M | -2.81M | -100.16M | -109.02M | -120.75M | - | 85.68M | -24.98M | -182.61M | -121.23M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 62.83M | 61.13M | 58.04M | 71.67M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -19.03M | -14.50M | -25.67M | -34.55M | -29.70M | -58.04M | -65.21M | -51.50M | -36.23M | -103.74M | -60.07M | -100.09M | - | -86.48M | 74.73M | -148.80M | -116.09M |
| Investing Cash Flow | -52.40M | 19.92M | 16.91M | -907.00K | 7.91M | 6.16M | -20.61M | -16.34M | -37.60M | 25.15M | -3.40M | -67.03M | - | -127.56M | 27.45M | 82.22M | 164.52M |
| Financing Cash Flow | 59.52M | -2.96M | 9.49M | 32.97M | 21.65M | 50.86M | 86.83M | 68.70M | 75.00M | 81.05M | 60.70M | 174.53M | - | 124.25M | -106.08M | 62.88M | -42.17M |
| Capital Expenditure | -279.00K | -807.00K | -1.24M | -642.00K | -204.00K | -28.00K | -240.00K | -126.00K | -350.00K | -567.00K | -334.00K | -283.00K | - | -113.00K | -426.00K | -165.00K | -65.00K |
| Free Cash Flow | -19.31M | -15.31M | -26.91M | -35.19M | -29.90M | -58.07M | -65.45M | -51.63M | -36.58M | -104.30M | -60.41M | -100.37M | - | -86.60M | 74.30M | -148.97M | -116.16M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | -89.80M | -3.90M | -3.71M | 6.26M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 4.65M | 11.85M | 0 |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | -67.7% | -375.7% | -130.6% | -212.6% | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | -82.5% | -424.4% | -75.6% | -187.0% | - | - | - | - | - |
| ROE % | -48.9% | -142.9% | 514.0% | 588.6% | 216.5% | 172.7% | 286.3% | 178.2% | 1,900.5% | 126.6% | 77.5% | 114.3% | - | 55.3% | 471.6% | 85.9% | 2.8% |
| ROCE % | - | -99.3% | -342.8% | -202.5% | -1,083.6% | 935.8% | -217.6% | -106.0% | -48.8% | -191.6% | -179.2% | -108.7% | - | -35.9% | -50.6% | -84.5% | -49.6% |
Shareholding Pattern
Insiders
3.56%
Institutions
44.41%
Public Float
46.05%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.34% | 5.31M | $58.62M |
| 2 | Ingalls & Snyder LLC | 4.92% | 3.56M | $39.30M |
| 3 | Vanguard Capital Management LLC | 4.12% | 2.98M | $32.94M |
| 4 | UBS Group AG | 3.23% | 2.34M | $25.84M |
| 5 | State Street Corporation | 2.65% | 1.92M | $21.19M |
| 6 | Stifel Financial Corporation | 2.53% | 1.83M | $20.22M |
| 7 | Geode Capital Management, LLC | 2.42% | 1.75M | $19.35M |
| 8 | Corient Private Wealth LLC | 1.11% | 801.41K | $8.85M |
| 9 | Vanguard Portfolio Management LLC | 0.99% | 718.67K | $7.93M |
| 10 | Charles Schwab Investment Management, Inc. | 0.80% | 582.51K | $6.43M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OMER
No recent headlines available.